Markets:

Overview

News

Currencies

International

Treasuries

OS Therapies Incorporated Common Stock (NY:OSTX)

1.725 +0.025 (+1.47%)

Streaming Delayed Price Updated: 10:22 AM EDT, Sep 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about OS Therapies Incorporated Common Stock

< Previous 1 2 3 4 5 Next >

OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing

Today 7:46 EDT

Overall Survival (OS) historical-control data gains HMRA and EMA support for pending CMAA submissionsFull alignment achieved on confirmatory Phase 3...

Via Newsfile

OS Animal Health Featured in Coverage of the Disruptive Growth & Life Sciences Conference

September 08, 2026

Via Investor Brand Network

OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial

September 08, 2026

71.2% 3-year overall survival for OST-HER2-treated patients vs. 45.8% comparable combined historical control (p = 0.002)The two remaining patients who...

Via Newsfile

InvestorNewsBreaks – OS Therapies Inc. (NYSE American: OSTX) Heads to Moody Capital Conference Amid Major OST-HER2 Regulatory Push

September 03, 2026

Via Investor Brand Network

OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance

September 02, 2026

Management will participate at Jefferies Global Healthcare Conference, H.C. Wainwright Global Investment Conference, ROTH Healthcare Opportunities Conference Management and business...

Via Newsfile

OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates

August 17, 2026

Up to $10 million debt financing supported by U.K. subsidiary VAT refunds and reimbursable R&D tax credits, including $5 million...

Via Newsfile

OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma

August 13, 2026

Meeting to occur in mid-September 2026Interim 3-year Overall Survival data expected early September, 2026Decisions on appropriate comparator arm to interpret...

Via Newsfile

OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program

July 08, 2026

New York, New York and Rockville, Maryland--(Newsfile Corp. - July 8, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS...

Via Newsfile

Topics Intellectual Property

OS Therapies Third Quarter 2026 Corporate Outlook

July 06, 2026

New York, New York and Rockville, Maryland--(Newsfile Corp. - July 6, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS...

Via Newsfile

OS Therapies Appoints Dr. Craig Eagle to Board of Directors

July 02, 2026

Company secures $10 million line of credit supported by OS Therapies UK tax creditsNew York, New York and Rockville, Maryland--(Newsfile...

Via Newsfile

OS Therapies Provides U.S. Regulatory Update

June 30, 2026

Type B Meeting requested to follow up on September 2025 End of Phase 2 FDA Meeting guidance on statistical methods...

Via Newsfile

OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma

June 26, 2026

20% of OST-HER2 treated dogs survived 2-year vs. 1% in control group (p = 0.00995)Over 15,000 dogs per year diagnosed...

Via Newsfile

OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma

June 08, 2026

Confirmatory Phase 3 trial to commence prior to BLA grant under Accelerated Approval Program in the U.S. and Conditional MAA...

Via Newsfile

Topics Intellectual Property

OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma

June 02, 2026

75% 2.5-year overall survival for OST-HER2 vs. 47% pooled historical control ...

Via Newsfile

Topics Death Intellectual Property

OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World

May 29, 2026

The Company confirms that it will release 2.5 year overall survival data from Phase 2b clinical trial OST-HER2 in the...

Via Newsfile

OS Therapies to Attend Upcoming Medical, Financial and Industry Conferences

May 26, 2026

ASCO 2026: 2.5-Year Overall Survival DataJefferies Healthcare Conference: Partnering & Investor meetingsBIO International Convention: Panel ParticipationMIB Agents Factor Osteosarcoma Conference:...

Via Newsfile

OS Therapies Reports First Quarter 2026 Financials and Provides Business Update

May 18, 2026

$5.5 million financing that closed on April 2, 2026 together with $5.7 million in capital raised in Q1-2026, expected to...

Via Newsfile

Topics Regulatory Compliance

OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026

May 15, 2026

New York, New York and Rockville, Maryland--(Newsfile Corp. - May 15, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS...

Via Newsfile

OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor

May 14, 2026

Appointment strengthens medical, regulatory, and commercial leadership as Company prepares to complete early market access regulatory filings in the U.S.,...

Via Newsfile

Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX)

May 12, 2026

Dallas, Texas--(Newsfile Corp. - May 12, 2026) - OS Therapies Inc. (NYSE American: OSTX): Stonegate Capital Partners updates their coverage...

Via Newsfile

OS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic Osteosarcoma

April 30, 2026

Conference call scheduled for Thursday, April 30, 2026, at 8:30 am ET to review new OST-HER2 immune pharmacodynamic biomarker response...

Via Newsfile

OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET

April 27, 2026

Regulatory feedback recent from April 2026 EU EMA and Australian TGA meetingsRemaining Q2-2026 regulatory meetings include two U.S. FDA meetings...

Via Newsfile

Topics Intellectual Property

OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes

April 16, 2026

New patent application covers treatment-emergent immune signature related to 'turning cold tumors hot' and the activation of targeted cytotoxic cellular...

Via Newsfile

Topics Intellectual Property

OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor

April 13, 2026

Co-founder of more than 40 biotechnology companies, including 16 IPOs and 19 successful acquisitions Scientific and medical titan focused on...

Via Newsfile

OS Therapies Investor News: Rosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation – OSTX

April 11, 2026

From The Rosen Law Firm, P.A.

Via Business Wire

Rosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation – OSTX

April 10, 2026

From The Rosen Law Firm, P.A.

Via Business Wire

OS Therapies Appoints Craig Eagle, MD as Strategic Advisor

April 08, 2026

Senior leadership roles at Guardant Health, Genentech and PfizerRegulatory, clinical and commercial expertise in therapeutics and biomarkersWill assist with osteosarcoma...

Via Newsfile

OS Therapies Completes $5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors

April 02, 2026

Company expects approximately $2 million in non-dilutive VAT refunds from wholly owned U.K. subsidiary in 2Q-26Company expects to receive approximately...

Via Newsfile

OS Therapies Completes Submission of Biomarker & Clinical Data for U.S. FDA Pre-BLA Meeting, Reports Full Year 2025 Financial Results and Provides Business Update

March 31, 2026

December 2025 Type C Meeting confirmed immune biomarkers suitability to establish surrogate clinical efficacy that could support BLA under Accelerated...

Via Newsfile

OS Therapies Granted Meetings with U.S. FDA, U.K. MHRA, EMA and Australian Therapeutic Goods Administration to Review Global Confirmatory Phase 3 Trial for OST-HER2 in Metastatic Osteosarcoma

March 27, 2026

Meetings with all four regulatory agencies scheduled to occur in the second quarter of 2026, with expected Phase 3 commencement...

Via Newsfile

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.